Too slow recruitment rate. The study has been terminated and will be re-started with an improved and more suitable study design.

The purpose of this study is to evaluate the efficacy of a novel therapy for treatment of migraine, pain reduction and relief of associated symptoms during ongoing migraine attacks, and presence of a preventive effect two months post treatment. Another purpose is to investigate if and how this treatment affects manifestations of the autonomic nervous system activity.

Inclusion Criteria:

• Female or male subjects, in otherwise good health, 20 to 55 years of age
• Subjects who meet the ICHD-2 (2nd Edition of The International Headache Classification) criteria for migraine headache
• Subjects with a minimum of 1 migraine attack per month
• Attack duration of 4 to 72 hours
• Normal attack intensity of at least 4 on a 0-10 VAS-scale

Exclusion Criteria:

• Completed heart surgery
• Cardiovascular diseases
• Vascular damages on neck vessels
• Diseases other than migraine of the CNS
• Severe disease of vital body organs
• Severe psychiatric disorders
• More than 6 migraine attacks per month